ATE355293T1 - Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten - Google Patents

Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten

Info

Publication number
ATE355293T1
ATE355293T1 AT02757132T AT02757132T ATE355293T1 AT E355293 T1 ATE355293 T1 AT E355293T1 AT 02757132 T AT02757132 T AT 02757132T AT 02757132 T AT02757132 T AT 02757132T AT E355293 T1 ATE355293 T1 AT E355293T1
Authority
AT
Austria
Prior art keywords
bicycloheptanes
aza
diseases
substituted
treatment
Prior art date
Application number
AT02757132T
Other languages
English (en)
Inventor
Donn G Wishka
Daniel Patrick Walker
Jeffrey W Corbett
Steven Charles Reitz
Mark R Rauckhorst
Vincent E Groppi Jr
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE355293T1 publication Critical patent/ATE355293T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02757132T 2001-09-12 2002-09-04 Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten ATE355293T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32233301P 2001-09-12 2001-09-12
US32210001P 2001-09-12 2001-09-12
US32234601P 2001-09-12 2001-09-12
US39953002P 2002-07-30 2002-07-30

Publications (1)

Publication Number Publication Date
ATE355293T1 true ATE355293T1 (de) 2006-03-15

Family

ID=27502238

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757132T ATE355293T1 (de) 2001-09-12 2002-09-04 Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten

Country Status (10)

Country Link
US (1) US20030105089A1 (de)
EP (1) EP1425286B1 (de)
JP (1) JP2005527472A (de)
AR (1) AR036779A1 (de)
AT (1) ATE355293T1 (de)
BR (1) BR0212477A (de)
CA (1) CA2460075A1 (de)
DE (1) DE60218493D1 (de)
MX (1) MXPA04002377A (de)
WO (1) WO2003022856A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0307782A (pt) * 2002-02-19 2005-01-04 Upjohn Co Compostos azabiciclo para o tratamento de doença
WO2003072578A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
CA2503786A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ES2462545T3 (es) 2002-12-06 2014-05-23 The Feinstein Institute For Medical Research Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico
BRPI0407714A (pt) * 2003-02-21 2006-02-14 Pharmacia & Up John Company Ll "exo-2r (+)-2-amino-7-azabiciclo[2.2.1]heptano-7-carboxilato de t-butila, intermediário, e processo para os preparar e isolar
EP1613307A4 (de) * 2003-04-07 2008-03-12 Glaxo Group Ltd M sb 3 /sb muscarinische acetylcholin-rezeptor-antagonisten
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
DE602004010299T2 (de) 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
JP2007534692A (ja) * 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
JP2007538011A (ja) 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
BRPI0517494A (pt) 2004-12-22 2008-10-14 Memory Pharm Corp composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20070049603A1 (en) * 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
WO2007068620A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
WO2008083124A1 (en) 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
JP5544296B2 (ja) 2007-11-16 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
ES2553340T3 (es) 2007-12-12 2015-12-07 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
JP5658138B2 (ja) 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
CA2894860C (en) 2008-11-19 2018-11-06 Gerhard Koenig Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2011022692A2 (en) * 2009-08-20 2011-02-24 University Of Tennessee Research Foundation, The Furanopyridine cannabinoid compounds and related methods of use
RU2560729C2 (ru) * 2010-01-11 2015-08-20 АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи Модуляторы никотиновых ацетилхолиновых рецепторов
MX357676B (es) 2010-05-17 2018-07-18 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
EA201390876A1 (ru) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
EP3666272A1 (de) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Verwendung von encenicline bei der behandlung von kognitiver behinderung, alzheimer-krankheit, speicherdefizit
WO2014017803A1 (ko) 2012-07-23 2014-01-30 주식회사 유한양행 퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물
US10154992B2 (en) 2016-07-12 2018-12-18 The Regents Of The University Of California Compounds and methods for treating HIV infection
JP7434285B2 (ja) * 2018-08-14 2024-02-20 アムジエン・インコーポレーテツド Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
CA3202092A1 (en) * 2020-11-18 2022-05-27 Elanco Tiergesundheit Ag Bicyclic derivatives

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA832549B (en) * 1982-04-14 1988-09-28 Beecham Group Plc Pharmaceutically active compounds
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
DE3429830A1 (de) * 1983-08-26 1985-03-07 Sandoz-Patent-GmbH, 7850 Lörrach Automatische carbonsaeure- und sulfonsaeureester oder -amide
US5175173A (en) * 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US5122528A (en) * 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
US4888353A (en) * 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0385517B1 (de) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Arzneimittel zur Behandlung von Erbrechen
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8520616D0 (en) * 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE3782107T2 (de) * 1986-07-25 1993-04-01 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
EP0551963A3 (en) * 1986-12-17 1993-09-01 Glaxo Group Limited Use of heterocyclic derivatives for the manufacture of medicaments
DE3788057T2 (de) * 1986-12-17 1994-03-03 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
US5322951A (en) * 1987-01-05 1994-06-21 Beecham Group, P.L.C. Certain 1-(2,3-dihydro-indole)carbonyl intermediates
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US4835162A (en) * 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3852145T2 (de) * 1987-02-18 1995-04-06 Beecham Group Plc Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
EP0289170B1 (de) * 1987-04-25 1993-06-23 Beecham Group Plc Azabicyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US4921982A (en) * 1988-07-21 1990-05-01 Eli Lilly And Company 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
CA1304082C (en) * 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
IE62231B1 (en) * 1987-12-24 1995-01-11 Wyeth John & Brother Ltd Heterocyclic compounds
US5246942A (en) * 1988-04-27 1993-09-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
EP0350130A3 (de) * 1988-07-07 1991-07-10 Duphar International Research B.V Substituierte 1,7-annelierte 1H-Indazole
US4920227A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US4933445A (en) * 1988-11-29 1990-06-12 Rorer Pharmaceutical Corporation Heteroazabenzobicyclic carboxamide 5-HT3 antagonists
US4920219A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents
EP0402056A3 (de) * 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5185333A (en) * 1989-07-03 1993-02-09 Yoshitomi Pharmaceutical Industries, Ltd. Benzazine compounds and pharmaceutical uses thereof
US4935511A (en) * 1989-09-26 1990-06-19 Rorer Pharmaceutical Corporation Benzoxazine and benzoxazepine carboxamide 5-HT3 antagonists
GB2236751B (en) * 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
US5342845A (en) * 1990-08-31 1994-08-30 Nippon Shinyaku Company Limited Indole derivatives and drugs
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
US5114947A (en) * 1990-12-27 1992-05-19 Erbamont Inc. Method for alleviating anxiety using benzobicyclic carboxamides
MX9102686A (es) * 1990-12-27 1994-01-31 Erba Carlo Spa Carboxamidas de dihidrobenzofurano y proceso para su preparacion.
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
JPH05310732A (ja) * 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
US5273972A (en) * 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
SE9201478D0 (sv) * 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
US5300512A (en) * 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US6060473A (en) * 1993-04-01 2000-05-09 Ucb S.A. - Dtb 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands
US6117889A (en) * 1994-04-01 2000-09-12 University Of Virginia 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
US5510486A (en) * 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5723103A (en) * 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
KR19980702644A (ko) * 1995-03-02 1998-08-05 오노다 마사요시 삼환식 헤테로 축합 환을 갖는 신규한 퀴누클리딘 유도체-
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
BR0212477A (pt) 2004-08-24
EP1425286A1 (de) 2004-06-09
JP2005527472A (ja) 2005-09-15
DE60218493D1 (de) 2007-04-12
MXPA04002377A (es) 2004-11-22
US20030105089A1 (en) 2003-06-05
AR036779A1 (es) 2004-10-06
EP1425286B1 (de) 2007-02-28
WO2003022856A1 (en) 2003-03-20
CA2460075A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE60124576D1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60233414D1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
DE60316538D1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE69829558D1 (de) Sulfonamide für die behandlung von störungen durch endothelin vermittelt
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60233069D1 (de) Zusammensetzungen aus curcuma extrakten für die behandlung von neurozerebrovaskulären erkrankungen
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
DZ3500A1 (fr) Derives de phenethanolamine pour le traitement de maladies respiratoires
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE60105614D1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
ATE355283T1 (de) Isochroman verbindungen für die behandlung von cns-krankheiten
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties